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The aim of this open-label phase 1b study was to assess the safety and pharmacokinetics of motesanib in combination with
gemcitabine in patients with advanced solid tumours. Eligible patients with histologically or cytologically documented solid tumours or
lymphoma were enroled in three sequential, dose-escalating cohorts to receive motesanib 50mg once daily (QD), 75mg two times
daily (BID), or 125mg QD in combination with gemcitabine (1000mgm
 2). The primary end point was the incidence of dose-
limiting toxicities (DLTs). Twenty-six patients were enroled and received motesanib and gemcitabine. No DLTs occurred. The 75mg
BID cohort was discontinued early; therefore, 125mg QD was the maximum target dose. Sixteen patients (62%) experienced
motesanib-related adverse events, most commonly lethargy (n¼6), diarrhoea (n¼4), fatigue (n¼3), headache (n¼3), and nausea
(n¼3). The pharmacokinetics of motesanib and of gemcitabine were not markedly affected after combination therapy. The objective
response rate was 4% (1 of 26), and 27% (7 of 26) of patients achieved stable disease. In conclusion, treatment with motesanib plus
gemcitabine was well tolerated, with adverse event and pharmacokinetic profiles similar to that observed in monotherapy studies.
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Angiogenesis, the process by which new blood vessels develop,
plays a critical role in tumour development and metastasis by
providing tumours with nutrients and oxygen (Folkman and
Shing, 1992). The proangiogenic cytokine vascular endothelial
growth factor (VEGF) promotes neovascularisation by binding and
activating VEGF receptor 2 (VEGFR2) and VEGFR1 (Ferrara et al,
2003). Solid tumours also express platelet-derived growth factor
receptor (PDGFR) and stem cell factor receptor (Kit); both have
been shown to play a role in the pathogenesis of several tumour
types (Heinrich et al, 2002; Yu et al, 2003). Inhibition of
angiogenesis has emerged as an effective treatment strategy in
some solid tumours (Yang et al, 2003; Miller et al, 2005; Sandler
et al, 2006).
Motesanib is a highly selective, oral inhibitor of angiogenesis
with direct antitumour activity. It inhibits VEGFR1, 2, and 3 (50%
inhibitory concentration (IC50)¼2, 3, and 6nM, respectively); and
PDGFR (IC50¼84nM) and Kit (IC50¼8n M), which may confer
direct antitumour activity (Polverino et al, 2006). In a phase 1
study, motesanib monotherapy in patients with advanced solid
tumours had tolerable toxicity and showed encouraging activity
against a number of tumour types, including sarcoma, renal cell
carcinoma, and thyroid cancer (Rosen et al, 2007).
Recent studies have suggested that combination treatment with
a VEGF inhibitor plus cytotoxic chemotherapy may result in
enhanced efficacy compared with single-agent approaches,
whereas maintaining a favourable adverse event profile (Miller
et al, 2005, 2007; Giantonio et al, 2007; Herbst et al, 2007; Heymach
et al, 2007). Gemcitabine, which has activity in many solid
tumours, has been combined with the monoclonal anti-VEGF
antibody bevacizumab for the treatment of hepatocellular carci-
noma or advanced pancreatic cancer (Kindler et al, 2005; Zhu et al,
2006). The aim of this study was to determine the maximum target
dose and the pharmacokinetic profile of motesanib when
administered in combination with gemcitabine in patients with
advanced solid tumours, and to assess the safety and efficacy of
this treatment regimen.
MATERIALS AND METHODS
Patients
Eligible adult (X18 years) patients had histologically or cytologi-
cally documented solid tumours or lymphoma; Eastern Coopera-
tive Oncology Group score zero to two; systolic/diastolic blood
pressure p145/p85mmHg; adequate cardiac, hepatic, and renal
function; and were candidates for gemcitabine treatment as
deemed by the investigator. Patients were ineligible if they had
received prior treatment with VEGF inhibitors or gemcitabine, had
received systemic chemotherapy within 21 days of study day 1 or
strong inhibitors of cytochrome P450 (CYP) 3A4 within 7 days of
study day 1. Other main exclusion criteria were: non-small cell
lung cancer (NSCLC) with squamous cell histology; large central
tumour lesions in the thorax (X3cm and located adjacent to or
within the hilum or mediastinum); evidence of active bleeding or Received 9 September 2008; accepted 16 September 2008
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sbleeding diathesis; and untreated or symptomatic brain metas-
tases. All patients provided written informed consent.
Study design
This was an open-label, phase 1b, dose-finding study conducted at
three centres in Australia. All study procedures were approved by
the respective independent ethics committee and/or institutional
review board. The primary end point was the incidence of
dose-limiting toxicities (DLTs). The secondary end point was
assessment of the pharmacokinetic profile of motesanib and
gemcitabine, respectively, when administered alone or in combi-
nation. The safety end points included incidence of adverse events,
serious adverse events, and laboratory abnormalities not defined
as DLTs. Exploratory end points included the response rate as
defined by modified Response Evaluation Criteria in Solid
Tumours (RECIST) (Therasse et al, 2000).
Dose escalation and target dose
Motesanib diphosphate (Amgen Inc., Thousand Oaks, CA, USA)
was self-administered continuously by mouth beginning on day 2
of cycle 1. Based on the range of tolerable doses explored in a
previous study (Rosen et al, 2007), patients were enroled in three
sequential, dose-escalating cohorts (up to six evaluable patients
each): motesanib 50mg once daily (QD) (starting dose), 75mg two
times daily (BID), or 125mg QD. Enrolment in the higher dose
cohorts began only if the initial 50-mg QD dose was well tolerated
(four or more patients with no DLTs). Dose escalation within
cohorts was not permitted. In the 125-mg QD cohort, if two or
fewer patients experienced a DLT in the first 4 weeks of treatment
this dose would be considered the target QD dose. Gemcitabine
(1000mgm
 2) was administered intravenously once weekly for 7
weeks followed by 1 week of rest (cycle 1), then once weekly for 3
weeks followed by 1 week of rest (cycles 2–11; all 4-week cycles).
Combination treatment continued for up to 48 weeks or until
disease progression or unacceptable toxicity occurred.
Dose delays and dose reductions were defined in the protocol
for both motesanib and gemcitabine according to treatment-
related toxicities.
Dose-limiting toxicities
DLTs were defined as grade 3 or higher toxicities occurring during
cycle 1 that were related to motesanib or to motesanib plus
gemcitabine. Fatigue, nausea, diarrhoea, vomiting, neutropenia,
febrile neutropenia, thrombocytopenia, anaemia, lymphopenia,
alopecia, hypertension, and increased aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) were excluded unless the
following criteria were met: grade 3 fatigue persisting for X7 days
or grade 4 fatigue; grade 3 or 4 nausea, vomiting or diarrhoea
despite maximum supportive care; grade 3 neutropenia with fever
438.51C or grade 4 neutropenia; grade 4 thrombocytopenia
persisting for 47 days; grade 4 anaemia; grade 4 hypertension;
AST or ALT 410 times the upper limit of normal.
Safety
Adverse events were collected throughout the study and classified
according to the Medical Dictionary for Regulatory Affairs (2008).
Severity was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 3.0
(2006). Blood pressure and haematology were assessed on each day
of a gemcitabine infusion. Blood biochemistry was assessed on day
1 of each cycle. Samples for urinalysis were collected during cycles
1, 2, and 3 and every other cycle thereafter.
Pharmacokinetics
Plasma samples for intensive pharmacokinetic analysis of mote-
sanib were collected on week 1 (day 2) and week 2 (day 1) of
cycle 1 at predose and 0.25, 0.5, 1, 2, 4, 6, 8 (a subset of patients),
12 (75-mg BID cohort only), and 24h postdose. Trough plasma
pharmacokinetic samples were collected on weeks 9, 13, 21, 29, 37,
and 45 or at the end of treatment. Plasma samples for gemcitabine
intensive pharmacokinetic analysis were collected for all dose
cohorts on week 1 (day 1) and week 2 (day 1) of cycle 1 at predose
and 15, 30, 45 (week 1 only), 60, and 120minutes after infusion
start.
Samples were analysed for motesanib (Amgen Inc., Thousand
Oaks, CA, USA) and gemcitabine concentrations (Quest Pharma-
ceutical Services, Newark, DE, USA) using validated liquid
chromatography/tandem mass spectrometry methods with a lower
limit of quantitation of 0.5 and 10ngml
 1, respectively.
Noncompartmental pharmacokinetic analyses were performed
using WinNonlin Professional software on Citrix (Version 5.1.1,
Pharsight Corporation, Mountain View, CA, USA) to estimate the
following pharmacokinetic parameters: maximum observed plas-
ma concentration (Cmax), time to Cmax (tmax), the terminal-phase
elimination half-life (t1/2,z), observed plasma concentration at 24h
postdose (C24) for motesanib, observed plasma concentration at
2h postdose (C2) for gemcitabine, and area under the concentra-
tion vs time curve from time 0 extrapolated to infinity (AUC0 inf)
and 0–24h (AUC0–24) for motesanib or 0–2h (AUC0–2) for
gemcitabine.
Tumour response
Computed tomography (CT) or magnetic resonance imaging
(MRI) for tumour assessments were performed at baseline and at
12-week intervals, or as clinically indicated. In patients with
baseline measurable disease tumour response per modified
RECIST (Therasse et al, 2000) was assessed by the investigator.
Complete and partial responses were confirmed using CT or MRI
scans no less than 28 days after the initial response.
Statistical analysis
The safety analysis set included all patients who received X1 dose
of motesanib. The pharmacokinetic analysis set included all
patients from the safety analysis set who had evaluable plasma
samples. The comparative pharmacokinetic analysis subset
included patients with evaluable Cmax values following single-dose
administration and multiple-dose administration in combination
with gemcitabine.
RESULTS
Patients
Twenty-six patients were enroled; all received at least one dose of
motesanib and one gemcitabine infusion. The demographic and
baseline characteristics are summarised in Table 1. The most
common tumour types were soft tissue sarcoma (15%), ovarian
(12%), pancreatic (12%), and neuroendocrine (8%). Most patients
(92%) had advanced disease, and had received prior chemotherapy
(65%) or radiation therapy (54%). All 26 patients discontinued
treatment with motesanib because of the following reasons: disease
progression (n¼14), withdrawal of consent (n¼5), administrative
decision (n¼3), adverse event (n¼2), death (n¼1), and patient
request (n¼1). Patients received treatment with motesanib on a
median of 75 days (minimum–maximum, 14–188), and received
a median of 7.5 gemcitabine infusions (minimum–maximum,
2–22).
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The first cohort (motesanib 50mg QD starting dose) enroled 11
patients to have six evaluable patients for the safety review (five
patients were deemed unevaluable per protocol criteria). No DLTs
occurred. The median treatment duration was 83 days (mini-
mum–maximum, 55–188). Six patients were then enroled in the
125-mg QD cohort. This dose had been previously established as
the motesanib maximum-tolerated dose in the first-in-human
study (Rosen et al, 2007). One DLT of grade 4 neutropenia
occurred that was considered (per investigator) to be related to
both motesanib and gemcitabine treatment. The 125-mg QD dose
was established as the target once-daily dose per protocol
definition (see Materials and Methods). A maximum-tolerated
dose was not determined in this study. As the 125-mg QD dose was
reasonably well tolerated, doses between 50mg and 125mg QD
were not tested. Patients in the 125-mg QD cohort received
motesanib treatment on a median of 53 days (minimum–
maximum, 20–181). The 75-mg BID cohort enroled nine patients.
No DLTs occurred. One patient had jugular vein thrombosis that
was considered by the study site to be not related to motesanib.
However, the cohort was discontinued early because an increased
incidence of cholecystitis, compared with the general population of
cancer patients, was observed at this dose level in other motesanib
studies (Amgen Inc., data on file). The median treatment duration
in this cohort was 34 days (minimum–maximum, 14–112).
Adverse events
Sixteen patients (62%) experienced motesanib treatment-related
adverse events, including several events of special interest
(Table 2). Hypertension was generally manageable with antihy-
pertensive treatment, although two patients (one in the 50-mg QD
cohort and one in the 75-mg BID cohort) had motesanib dose
reductions to control hypertension, and treatment was withheld in
one patient in the 125-mg QD cohort. Two grade 3 motesanib-
related adverse events (lethargy, considered related to both
motesanib and gemcitabine treatment, and deep vein thrombosis;
75-mg BID cohort) and 1 grade 4-related event (neutropenia; 125-
mg QD cohort) occurred. Serious related events were grade 2
dehydration and lethargy (50-mg QD cohort); and grade 3 deep
vein thrombosis (75-mg BID cohort). No cases of cholecystitis
occurred. Three patients died during the study. The deaths were
attributed to disease progression (50-mg QD cohort), renal failure
(50-mg QD cohort), and Pneumocystis jiroveci pneumonia (75-mg
BID cohort), respectively. All deaths were unrelated to motesanib
treatment.
Table 1 Demographic and clinical characteristics of study patients
Motesanib dose cohort
Characteristics 50mg QD (n¼11) 125mg QD (n¼6) 75mg BID (n¼9) All patients (n¼26)
Men, n (%) 5 (45) 3 (50) 6 (67) 14 (54)
Race,n(%)
White 11 (100) 6 (100) 8 (89) 25 (96)
Hispanic or Latino 0 (0) 0 (0) 1 (11) 1 (4)
Median age, years (minimum–maximum) 57.0 (34–76) 49.5 (25–66) 57.0 (32–77) 56.5 (25–77)
ECOG performance status,n(%)
0 5 (45) 3 (50) 4 (44) 12 (46)
1 5 (45) 3 (50) 5 (56) 13 (50)
2 1 (9) 0 (0) 0 (0) 1 (4)
Tumour type,n(%)
Soft-tissue sarcoma 2 (18) 1 (17) 1 (11) 4 (15)
Ovarian 2 (18) 1 (17) 0 (0) 3 (12)
Pancreatic 2 (18) 0 (0) 1 (11) 3 (12)
Neuroendocrine 1 (9) 1 (17) 0 (0) 2 (8)
Bile duct 0 (0) 0 (0) 1 (11) 1 (4)
Bladder 0 (0) 1 (17) 0 (0) 1 (4)
Breast 1 (9) 0 (0) 0 (0) 1 (4)
Colon 0 (0) 1 (17) 0 (0) 1 (4)
Oesophageal 0 (0) 0 (0) 1 (11) 1 (4)
Gall bladder 0 (0) 0 (0) 1 (11) 1 (4)
Non-small cell lung 0 (0) 0 (0) 1 (11) 1 (4)
Other
a 3 (27) 1 (17) 3 (33) 7 (27)
Prior chemotherapy,n(%)
0 2 (18) 3 (50) 4 (44) 9 (35)
1 1 (9) 1 (17) 2 (22) 4 (15)
2 5 (45) 0 (0) 2 (22) 7 (27)
X3 3 (27) 2 (33) 1 (11) 6 (23)
Prior radiation therapy,n(%)
0 6 (55) 2 (33) 4 (44) 12 (46)
1 2 (18) 4 (67) 4 (44) 10 (38)
2 1 (9) 0 (0) 1 (11) 2 (8)
3 2 (18) 0 (0) 0 (0) 2 (8)
BID¼two times daily; ECOG¼Eastern Cooperative Oncology Group; QD¼once daily.
aOne patient in the 125-mg QD dose cohort had Burkitt’s lymphoma.
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Mean (s.d.) plasma motesanib concentration vs time profiles and a
summary of pharmacokinetic parameters for intensive pharmaco-
kinetic sampling on day 2 of week 1 and day 1 week 2 are shown in
Figure 1 and Table 3, respectively. After single-dose oral
administration, motesanib was rapidly absorbed, with an overall
median tmax ranging from 0.5 to 1.5h for all three dose cohorts.
Similar overall median tmax values (0.83–2.0h) were observed after
multiple-dose administration in combination with gemcitabine.
The mean t1/2,z values ranged from 3.8 to 5.7h after single-dose
administration and from 4.3 to 5.0h after multiple-dose admin-
istration in combination with gemcitabine; these values did not
appear to be dose- or time-dependent.
The mean daily trough plasma concentrations (C24) for the
50-mg QD cohort were below the in vitro IC50 of human umbilical
vein endothelial cell (HUVEC) proliferation (IC50¼4ng/ml)
(Polverino et al, 2006) during cycle 1 but were above the IC50
during cycle 2. Mean C24 values for both week 1 and week 2 were
above the IC50 for the 125-mg QD cohort, and were above the
in vitro 90% inhibitory concentration (IC90) of HUVEC prolifera-
tion (IC90¼28ng/ml; Amgen Inc., data on file) for the 75-mg BID
cohort.
The Cmax values (week 1) for the 125-mg QD cohort were
comparable to those observed in the monotherapy study (Rosen
et al, 2007). However, motesanib Cmax (except 125mg QD, week 1)
and AUC values for week 1 and 2 in the QD cohorts were slightly
lower (o50% decrease) than the values observed in the motesanib
monotherapy study.
Pharmacokinetics of gemcitabine
Mean (s.d.) plasma gemcitabine concentration vs time profiles and
a summary of pharmacokinetic parameters for intensive pharma-
cokinetic sampling on day 1 of week 1 and week 2 from all
evaluable patients are shown in Figure 2 and Table 4, respectively.
Across motesanib dose groups, values for Cmax and AUC0–2 in
week 1 ranged from 9720 to 10900ngml
 1 and from 4.72 to
6.27mghml
 1, respectively; in week 2, these values ranged from
11400 to 13800ngml
 1 and from 6.56 to 7.92mghml
 1, respec-
tively. For all motesanib dose groups, the mean gemcitabine Cmax
Table 2 Motesanib treatment-related adverse events
Motesanib dose cohort
50mg QD
(n¼11)
125mg QD
(n¼6)
75mg BID
(n¼9)
All patients
(n¼26)
Patients with motesanib-related adverse events,n(%) 6 (55) 4 (67) 6 (67) 16 (62)
Lethargy 3 (27) 0 (0) 3 (33) 6 (23)
Diarrhoea 2 (18) 1 (17) 1 (11) 4 (15)
Fatigue 0 (0) 1 (17) 2 (22) 3 (12)
Headache 1 (9) 2 (33) 0 (0) 3 (12)
Nausea 1 (9) 1 (17) 1 (11) 3 (12)
Anorexia 0 (0) 0 (0) 2 (22) 2 (8)
Vomiting 1 (9) 0 (0) 1 (11) 2 (8)
Patients with motesanib-related adverse events of interest,n(%)
a
Hematemesis 0 (0) 0 (0) 1 (11) 1 (4)
Grade X3 0 (0) 0 (0) 0 (0) 0 (0)
Deep vein thrombosis 0 (0) 0 (0) 1 (11) 1 (4)
Grade 3 0 (0) 0 (0) 1 (11) 1 (4)
Hypertension 0 (0) 0 (0) 1 (11) 1 (4)
Grade X3 0 (0) 0 (0) 0 (0) 0 (0)
Neutropenia 0 (0) 1 (17) 0 (0) 1 (4)
Grade 4 0 (0) 1 (17) 0 (0) 1 (4)
BID¼two times daily; QD¼once daily.
aIncluding highest worst grade.
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Figure 1 Mean plasma concentration vs time profiles for motesanib after single-dose administration (week 1, day 2) (A) and multiple-dose administration
in combination with gemcitabine (week 2, day 1) (B). Data are means (s.d.). BID¼two times daily; QD¼once daily.
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(o2-fold) in week 2 compared with week 1.
Tumour response
Of the 26 patients enroled, one patient in the 125-mg QD dose
cohort with stage IV bladder cancer had a confirmed partial
response (Table 5). Of patients with a best response of stable
disease at 52 days (7 of 26), two had primary diagnoses of
pancreatic cancer (50-mg QD cohort); the others had diagnoses of
breast cancer (50mg QD), ovarian cancer (50mg QD), soft tissue
sarcoma (125mg QD), neuroendocrine cancer (125mg QD), and
other (75mg BID), respectively. No patients achieved durable
stable disease X24 weeks. Forty-six percent of patients (12 of 26)
had progressive disease as their best response.
DISCUSSION
Inhibition of angiogenesis has emerged as an effective therapy with
acceptable tolerability in a variety of different solid tumours,
including colorectal cancer (Hurwitz et al, 2004), NSCLC (Sandler
Table 3 Pharmacokinetic parameter estimates of motesanib after single-dose administration and after multiple-dose with gemcitabine administration
Parameter
After single-dose motesanib administration
(week 1, day 2)
After multiple-dose motesanib administration in combination with
gemcitabine (week 2, day 1)
50mg QD n n
tmax, h (range) 10 0.5 (0.25–6.0) 11 1.0 (0.28–4.0)
Cmax,n gm l
 1 (s.d.) 10 208 (147) 11 176 (136)
C24,n gm l
 1 (s.d.) 8 3.21 (1.80) 10 8.36 (14.1)
AUC0–24, mghml
 1 (s.d.) 8 0.630 (0.208) 10 0.764 (0.526)
AUC0–inf, mghml
 1 (s.d.) 8 0.656 (0.219) NR NR
t1/2,z, h (s.d.) 8 5.17 (0.873) 7 4.32 (0.668)
CL/F, L/h (s.d.) 8 83.7 (26.0) 10 106 (83.4)
75mg BID
a nn
tmax, h (range) 9 0.57 (0.25–2.0) 8 0.83 (0.25–4.0)
Cmax,n gm l
 1 (s.d.) 9 345 (266) 8 515 (463)
C12,n gm l
 1 (s.d.) 9 57.2 (46.5) 7 100 (137)
C24,n gm l
 1 (s.d.) 8 74.7 (83.7) 6 29.5 (20.9)
AUC0–24, mghml
 1 (s.d.) 9 2.76 (1.95) 7 4.96 (5.83)
AUC0–inf, mghml
 1 (s.d.) NR NR NR NR
t1/2,z, h (s.d.) 7 5.65 (2.21) 7 4.99 (1.98)
CL/F, L/h (s.d.) 9 152 (235) 7 239 (468)
125mg QD n n
tmax, h (range) 6 1.5 (0.33–4.0) 5 2.0 (0–2.0)
Cmax,n gm l
 1 (s.d.) 6 421 (194) 5 184 (96.1)
C24,n gm l
 1 (s.d.) 5 6.90 (4.60) 4 5.71 (3.38)
AUC0–24, mghml
 1 (s.d.) 5 1.90 (0.450) 4 1.24 (0.535)
AUC0–inf, mghml
 1 (s.d.) 6 1.70 (0.734) NR NR
t1/2,z, h (s.d.) 6 3.80 (1.40) 4 4.60 (0.594)
CL/F, L/h (s.d.) 6 102 (88.1) 4 124 (74.4)
AUC0–inf¼area under the plasma concentration versus time curve from time 0 to infinity; AUC0–24¼area under the plasma concentration versus time curve from time 0–24h
postdose; BID¼two times daily; CL/F¼apparent clearance; Cmax¼maximum observed concentration after dosing; C12¼observed concentration at 12h postdose;
C24¼observed concentration at 24h postdose; NR¼not reported; QD¼once daily; tmax¼time of Cmax; t1/2,z¼estimated terminal elimination half-life.
aFor the 75-mg BID
dose cohort, t1/2,z values were estimated based on the terminal slope after the first dose on week 1 or 2, AUC0–24values were estimated using 2 AUC0–12, and CL/F was
estimated by total daily dose/(2 AUC0–12).
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Figure 2 Mean plasma concentration vs time profiles for gemcitabine (1000mgm
 2 i.v.) administered alone (week 1, day 1) (A) or in combination with
motesanib (week 2, day 1) (B). Data are means (s.d.). BID¼two times daily; i.v.¼intravenous; QD¼once daily.
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set al, 2006), and breast cancer (Miller et al, 2007). Recent studies
have suggested that treatment with an antiangiogenic agent in
combination with cytotoxic chemotherapy can result in increased
antitumour efficacy, compared with chemotherapy alone, while
maintaining a tolerable safety profile (Miller et al, 2005; Giantonio
et al, 2007; Herbst et al, 2007). Motesanib is a highly specific
inhibitor of VEGFR1, 2, and 3; of PDGFR, and Kit (Polverino et al,
2006), all of which have been implicated as key regulators of
angiogenesis, lymphangiogenesis, and tumour cell proliferation
(Heinrich et al, 2002; Ferrara et al, 2003; Yu et al, 2003). In the
first-in-human monotherapy study, motesanib showed encoura-
ging efficacy and acceptable toxicity in patients with advanced
solid tumours (Rosen et al, 2007). In the study reported here,
combination therapy with motesanib 125mg QD plus gemcitabine
(1000mgm
 2) was well tolerated and 125mg QD was established
as the maximum target dose. Adverse events considered related to
motesanib were generally of mild to moderate severity. The overall
safety profile was similar to that observed in a previous
monotherapy study (Rosen et al, 2007), and was comparable to
results reported from monotherapy studies of other VEGF
inhibitors (Yang et al, 2003; Herbst et al, 2005; Motzer et al,
2006) and those from chemotherapy combination studies (Kindler
et al, 2005; Richly et al, 2006; Heymach et al, 2007). Similarly,
specific adverse events typically associated with VEGF inhibition,
such as hypertension, bleeding, or thromboembolic events, did not
occur more frequently in the study described here than in
monotherapy studies of other VEGF inhibitors (Herbst et al,
2005) or in gemcitabine combination studies, such as a phase 2
trial of bevacizumab plus gemcitabine in advanced pancreatic
cancer (Kindler et al, 2005). Of note, other toxicities, for example,
dermatologic toxicities, frequently reported with certain VEGFR
and PDGFR inhibitors both as single-agent treatment (Escudier
et al, 2007) or in combination with cytotoxic chemotherapy
(Richly et al, 2006) did not occur in this study. Gemcitabine
coadministration did not affect the tolerability profile of motesanib
in this clinical trial. This finding is consistent with prior studies,
which demonstrated that the addition of cytotoxic chemotherapy
did not significantly alter the safety profile of other tyrosine kinase
inhibitors including sorafenib (Richly et al, 2006) and vandetanib
(Heymach et al, 2007). Although no cases of cholecystitis occurred
in this study, the 75-mg BID dose cohort was discontinued early
because of an increased risk of cholecystitis in patients who
received this dose in other motesanib studies. The cause and
relation to motesanib is unknown and is currently under
investigation. Acute cholecystitis related to treatment with multi-
kinase inhibitors was earlier reported only once in a patient
receiving sunitinib (Motzer et al, 2006).
The pharmacokinetics of motesanib and gemcitabine were not
markedly affected by coadministration of the other compound.
The Cmax and AUC values for motesanib on week 2 compared with
week 1 varied across dose groups. Moreover, there was no
apparent trend of increasing or decreasing motesanib exposure
Table 4 Pharmacokinetic parameter estimates for 1000mgm
 2 intravenous gemcitabine administered alone (week 1, day 1) or in combination with
motesanib (week 2, day 1)
Parameter Administered alone (week 1, day 1) Administered in combination with motesanib (week 2, day 1)
50mg QD nn
tmax, h (range) 11 0.5 (0.13–0.75) 7 0.5 (0.25–0.50)
Cmax,n gm l
 1 (s.d.) 11 9720 (3240) 7 13800 (7530)
C2,n gm l
 1 (s.d.) 11 104 (60) 7 183 (143)
AUC0–2, mghml
 1 (s.d.) 11 5.21 (1.57) 7 7.92 (3.59)
75mg BID nn
tmax, h (range) 9 0.5 (0.25–0.75) 5 0.5 (0.5–1.0)
Cmax,n gm l
 1 (s.d.) 9 10900 (6230) 5 12800 (4080)
C2,n gm l
 1 (s.d.) 9 101 (92) 5 234 (360)
AUC0–2, mghml
 1 (s.d.) 9 6.27 (2.94) 5 7.09 (2.37)
125mg QD nn
tmax, h (range) 6 0.38 (0.18–0.75) 5 0.25 (0.25–0.50)
Cmax,n gm l
 1 (s.d.) 6 10000 (4460) 5 11400 (4010)
C2,n gm l
 1 (s.d.) 6 88 (88) 5 133 (96)
AUC0–2, mghml
 1 (s.d.) 6 4.72 (2.18) 5 6.56 (2.33)
AUC0–2¼area under the plasma concentration versus time curve from time 0–2h postdose; BID¼two times daily; C2¼observed concentration at 2h postdose;
Cmax¼maximum observed concentration after dosing; QD¼once daily; tmax¼time of Cmax.
Table 5 Best tumour response per modified RECIST as assessed by investigator
Motesanib dose cohort
50mg QD (n¼11) 125mg QD (n¼6) 75mg BID (n¼9) All patients (n¼26)
Patients with measurable disease at baseline, n (%) 11 (100) 6 (100) 9 (100) 26 (100)
Response assessment, n (%)
Confirmed complete response
a 0 (0) 0 (0) 0 (0) 0 (0)
Confirmed partial response
a 0 (0) 1 (17) 0 (0) 1 (4)
Stable disease 4 (36) 2 (33) 1 (11) 7 (27)
Progressive disease 7 (64) 3 (50) 2 (22) 12 (46)
Not done 0 (0) 0 (0) 6 (67) 6 (23)
Confirmed objective response
b, % (95% CI) 0 (0.0–28.5) 17 (0.4–64.1) 0 (0.0–33.6) 4 (0.1–19.6)
aPatients with a response assessment of complete response or partial response that was not confirmed at least 4 weeks later are reported as stable disease.
bObjective response
is defined as a tumour response assessment of either confirmed complete response or confirmed partial response.
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motesanib. An effect was not expected because, unlike motesanib,
gemcitabine is not metabolised by CYP3A4 (Shipley et al, 1992;
Mini et al, 2006). Exposure to motesanib in patients in the 50-mg
QD and 125-mg QD dose cohorts was similar (although slightly
lower) to that observed in a previous monotherapy study (Rosen
et al, 2007). The 75-mg BID dose has not been tested in
monotherapy studies and, therefore, no comparison of pharma-
cokinetic parameters and trough concentrations can be made.
Although mean gemcitabine concentrations on week 2 were
slightly higher than those on week 1, exposure to gemcitabine,
both alone and in combination with motesanib, was no greater
than the exposure observed in previous studies investigating
gemcitabine monotherapy (Cattel et al, 2006; Gietema et al, 2006).
Of the 26 patients enroled in this study, one achieved a
confirmed partial response and seven achieved stable disease as
their best tumour response. Although interpretation of the efficacy
results is limited by the small sample size and the exploratory
nature of this end point, the data support further exploration in
larger studies, which is also encouraged by the recent experience
with other combination treatments. Specifically, the addition of
VEGF inhibitors to cytotoxic chemotherapy has been shown to
enhance antitumour activity, compared with single-agent chemo-
therapy treatment (Miller et al, 2005, 2007; Giantonio et al, 2007;
Herbst et al, 2007; Heymach et al, 2007). In particular, preliminary
results from a phase 3 study in patients with advanced NSCLC have
suggested that improved efficacy can be achieved when combining
a VEGF inhibitor with a chemotherapy regimen that includes
gemcitabine and cisplatin (Manegold et al, 2005). Progression-free
survival was longer among patients who received bevacizumab
plus gemcitabine/oxaliplatin compared with patients treated with
gemcitabine/oxaliplatin plus placebo (6.7 vs 6.1 months) (Mane-
gold et al, 2005). On the other hand, preliminary results from
another phase 3 study suggest that treatment of advanced
pancreatic cancer with bevacizumab and gemcitabine does not
improve survival, although the proportion of patients with an
objective response or stable disease was slightly greater (54 vs
47%) (Kindler et al, 2007). Interestingly, preclinical evidence has
suggested that inhibition of PDGFR, which regulates vascular
survival and is expressed in most common solid tumours, may
play an important role in enhancing the therapeutic effect of
cytotoxic chemotherapy (Pietras et al, 2002). The potential efficacy
of motesanib, which inhibits both VEGFR and PDGFR, in
combination with gemcitabine or chemotherapy in general,
warrants further investigation in larger studies.
In conclusion, treatment with motesanib 125mg QD plus
gemcitabine was well tolerated, with adverse event and pharma-
cokinetic profiles similar to those observed in motesanib mono-
therapy studies. The 125-mg QD dose in combination with
cytotoxic chemotherapy is being investigated in larger studies to
further evaluate safety and efficacy.
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